MD Anderson and Cellectis announce broad preclinical and clinical strategic alliance
Cellectis and MD Anderson have entered into a R&D alliance aimed at bringing novel cellular immunotherapies to patients suffering from different types of liquid tumors. The alliance is aimed at developing novel cancer immunotherapies based on Cellectis' allogeneic chimeric antigen receptor platform. September 03, 2015